Breo Ellipta combines fluticasone furoate and vilanterol for maintenance treatment. Age and condition determine which strength is labeled, and the shared Ellipta device name does not make it the same medicine as Trelegy.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | fluticasone furoate / vilanterol (as vilanterol trifenatate) |
| Medicine class | Inhaled corticosteroid / long-acting beta2 agonist (ICS/LABA) |
| Forms and strengths | Ellipta dry-powder inhaler: 50/25, 100/25 and 200/25 mcg per actuation |
Two ingredients in an Ellipta device
Breo Ellipta contains the corticosteroid fluticasone furoate and the long-acting bronchodilator vilanterol. The cited strengths are 50/25, 100/25 and 200/25 mcg per actuation. It is a two-ingredient product; another inhaler using the Ellipta name may contain additional or different medicines.
Source: [1]
Match the strength to age and indication
US labeling covers COPD maintenance and asthma maintenance from age 5. The 50/25 presentation is specified for asthma at ages 5 to 11, 100/25 at ages 12 to 17, and adult asthma has 100/25 or 200/25 options. COPD uses 100/25. These distinctions are reference information, not personal selection advice.
Source: [1]
Once-daily maintenance and mouth rinsing
The product is used once daily under the prescribed plan and is not indicated for acute bronchospasm. Follow the Ellipta instructions for opening, inhalation and the dose counter. Rinse with water and spit afterward. Extra maintenance doses should not replace the separate plan for sudden breathing symptoms.
Source: [1]
Milk allergy and corticosteroid precautions
Severe milk-protein allergy or hypersensitivity to ingredients is a contraindication. The label warns about oral thrush, pneumonia in COPD, adrenal effects and possible bone, growth and eye effects. New or worsening infection symptoms or unexpected breathing deterioration need assessment. Do not stop other corticosteroids abruptly without a clinician's plan.
Source: [1]
Check overlap before adding another inhaler
Another LABA-containing medicine can create overdose risk, and strong CYP3A4 inhibitors require an interaction check. Bring all inhalers to the review, including any recently replaced device. A comparison with triple therapy can clarify ingredients, but does not establish that a third component is needed or justify an independent change.
The Breo Ellipta and Trelegy Ellipta comparison provides a separate side-by-side reference, without establishing an individual treatment choice.
Source: [1]
Questions and answers
Is Breo Ellipta a triple-therapy inhaler?
No. It contains two active medicines: fluticasone furoate and vilanterol.
Is the lowest Breo strength the COPD strength?
Not in the cited US label. COPD uses 100/25; 50/25 is the labeled asthma presentation for ages 5 to 11.
Does the Ellipta name tell me all the ingredients?
No. Ellipta identifies a device family. Read the product name and active ingredients on the prescribed pack.
Related reading
Sources
Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026